Bernstein Maintains Outperform on Exact Sciences, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst Eve Burstein has maintained an Outperform rating on Exact Sciences (NASDAQ:EXAS) and raised the price target from $75 to $90.
October 30, 2024 | 6:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bernstein has reaffirmed its Outperform rating on Exact Sciences and increased the price target from $75 to $90, indicating a positive outlook.
The increase in price target from $75 to $90 by Bernstein suggests a positive outlook for Exact Sciences, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100